Avadel Pharmaceuticals plc (AVDL)
21.64
+0.01 (0.05%)
Inactive · Last trade price on Feb 11, 2026
Avadel Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 165.36 | 51.37 | 31.17 | 73.98 | 50.71 |
Short-Term Investments | - | 22.41 | 73.94 | 22.52 | 106.51 |
Cash & Short-Term Investments | 165.36 | 73.78 | 105.11 | 96.5 | 157.22 |
Cash Growth | 124.14% | -29.81% | 8.92% | -38.62% | -29.46% |
Accounts Receivable | 49.83 | 34.1 | 12.1 | - | - |
Other Receivables | - | - | - | 2.25 | 31.54 |
Receivables | 49.83 | 34.1 | 12.1 | 2.25 | 31.54 |
Inventory | 25.19 | 20.3 | 10.38 | - | - |
Prepaid Expenses | 17.15 | 5.15 | 4.37 | 1.52 | 3.18 |
Other Current Assets | 0.71 | 0.88 | 2.24 | 0.57 | 0.55 |
Total Current Assets | 258.24 | 134.21 | 134.2 | 100.84 | 192.49 |
Property, Plant & Equipment | 9.71 | 12.86 | 13.08 | 13.24 | 11.49 |
Goodwill | 16.84 | 16.84 | 16.84 | 16.84 | 16.84 |
Long-Term Deferred Tax Assets | - | - | - | - | 24.13 |
Other Long-Term Assets | 0.28 | 0.34 | 0.58 | 1.87 | 2.33 |
Total Assets | 285.07 | 164.24 | 164.7 | 132.79 | 247.27 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 8.01 | 7.33 | 11.43 | 7.89 | 7.68 |
Accrued Expenses | 32.61 | 26.43 | 19.45 | 8.51 | 12.03 |
Current Portion of Long-Term Debt | - | - | 0.73 | 37.67 | - |
Current Portion of Leases | 0.76 | 0.58 | 0.93 | 0.96 | 0.9 |
Current Income Taxes Payable | 12.14 | - | - | - | - |
Other Current Liabilities | 22.46 | 14.49 | 4.31 | 0.77 | 0.39 |
Total Current Liabilities | 75.98 | 48.83 | 36.86 | 55.79 | 21 |
Long-Term Debt | 34.09 | 35.25 | 32.76 | 91.61 | 142.4 |
Long-Term Leases | 1.62 | 1.12 | 1.69 | 0.78 | 1.71 |
Other Long-Term Liabilities | 2.13 | 5.18 | 5.65 | 5.74 | 3.92 |
Total Liabilities | 113.82 | 90.39 | 76.96 | 153.93 | 169.02 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.98 | 0.97 | 0.9 | 0.63 | 0.59 |
Additional Paid-In Capital | 923.58 | 891.79 | 855.45 | 589.78 | 549.35 |
Retained Earnings | -729.66 | -794.33 | -745.5 | -585.22 | -447.76 |
Comprehensive Income & Other | -23.66 | -24.58 | -23.17 | -26.34 | -23.94 |
Total Common Equity | 171.25 | 73.85 | 87.69 | -21.15 | 78.24 |
Shareholders' Equity | 171.25 | 73.85 | 87.74 | -21.15 | 78.24 |
Total Liabilities & Equity | 285.07 | 164.24 | 164.7 | 132.79 | 247.27 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 36.46 | 36.95 | 36.11 | 131.02 | 145 |
Net Cash (Debt) | 128.9 | 36.82 | 69 | -34.52 | 12.22 |
Net Cash Growth | 250.04% | -46.63% | - | - | -86.77% |
Net Cash Per Share | 1.28 | 0.39 | 0.86 | -0.57 | 0.21 |
Filing Date Shares Outstanding | 98.3 | 96.63 | 90.58 | 64.48 | 59.03 |
Total Common Shares Outstanding | 98.09 | 96.52 | 89.83 | 62.88 | 58.62 |
Working Capital | 182.26 | 85.37 | 97.35 | 45.05 | 171.49 |
Book Value Per Share | 1.75 | 0.77 | 0.98 | -0.34 | 1.33 |
Tangible Book Value | 154.42 | 57.01 | 70.85 | -37.99 | 61.4 |
Tangible Book Value Per Share | 1.57 | 0.59 | 0.79 | -0.60 | 1.05 |
Machinery | 0.33 | 0.63 | 0.63 | 0.63 | 0.3 |
Construction In Progress | 0.56 | - | - | - | - |